Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
M Bronstein, University of São Paulo Medical School, Brazil
The efficacy and safety of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, will be assessed in 359 patients from 116 sites in 27 countries with active acromegaly versus octreotide LAR (20 mg). Patients will be dosed once every 28 days for 12 months, with titrations at 3 and 7 months as required. Results from this large, randomised, Phase III study will help determine the efficacy and safety of pasireotide LAR in the treatment of patients with active acromegaly.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.